# Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients

> **NCT04046094** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Ascorbic Acid

## Key facts

- **NCT ID:** NCT04046094
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-17
- **Primary completion:** 2022-09-12
- **Final completion:** 2026-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04046094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04046094, "Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04046094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*